Conventional versus minimally invasive extra-corporeal circulation in patients undergoing cardiac surgery: a randomised controlled trial
| ISRCTN | ISRCTN92590475 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN92590475 |
| Secondary identifying numbers | CPMS 36468 |
- Submission date
- 18/12/2017
- Registration date
- 18/01/2018
- Last edited
- 29/02/2024
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Circulatory System
Plain English Summary
Background and study aims
Miniaturised heart-lung machines (minimally invasive extracorporeal circulation; MiECC) have been developed with the aim of reducing the number of post-operative complications arising from using conventional heart-lung machines (CECC). Due to the variety of miniaturised systems that have been evaluated, the different types of patients and outcomes investigated, and the poor quality of previous studies, the effectiveness of MiECC in reducing post-operative complications has not been established and most hospitals continue to use CECC. Compared to CECC, using MiECC during cardiac surgery may reduce the proportion of patients having one of several serious postoperative complications (death, heart attack, stroke, gut infarction, severe acute kidney injury, reintubation, tracheostomy, mechanical ventilation for more than 48 hours, or reoperation). In addition, MiECC may reduce the amount of blood products transfused, time to discharge from the cardiac intensive care unit and hospital and the health care resources used during the hospital stay. The aim of this study is to evaluate the MiECC system and to detect if there is a reduction in risks as compared to the CECC.
Who can participate?
Adults aged 18 to 85 who are undergoing any elective or urgent coronary artery bypass surgery, aortic valve replacement or both using a heart-lung machine without circulatory arrest.
What does the study involve?
Participants are randomly allocated to one of two groups. Participants in the first group undergo surgery using the MiECC system. Those in the second group undergo surgery using CECC. Participants are followed up twice, at 30 days and at 90 days after surgery to look at the serious adverse events and their health quality of life.
What are the possible benefits and risks of participating?
The risks of having cardiac surgery are different from person to person, depending on the severity of heart disease, type of operation, age, and current state of health. Both types of heart and lung machines are used currently for heart operations in the NHS. At present, hospitals can choose either machine as there is little evidence to decide which machine is better.
Where is the study run from?
1. Bristol Royal Infirmary (UK)
2. Derriford Hospital (UK)
3. Hammersmith Hospital (UK)
4. Castle Hill Hospital (UK)
5. Royal Papworth Hospital (UK)
6. Aristotle University of Thessaloniki (Greece)
7. Inselspital, Universitätsspital Bern (Switzerland)
8. Universitätsklinikum Ulm (Germany)
9. Klinikum Braunschweig (Germany)
10. Ankara Numune Egitim Arastirma Hastanesi (Turkey)
11. Saud Al Babtain Cardiac Center (Saudi Arabia)
When is the study starting and how long is it expected to run for?
January 2017 to December 2020
Who is funding the study?
British Heart Foundation (BHF) (UK)
Who is the main contact?
Mr Jonathan Evans (Scientific), comics-trial@bristol.ac.uk
Professor Gianni Angelini – Chief Investigator
Professor Kyriakos Anastasiadis – Principal Investigator, Lead for EU-Countries
Professor Thierry Carrel – Principal Investigator, Lead for Non-EU Countries
Contact information
Scientific
Clinical Trials and Evaluation Unit
University of Bristol
Bristol Royal Infirmary
Bristol
BS2 8HW
United Kingdom
| Phone | +44 117 923 0000 |
|---|---|
| comics-trial@bristol.ac.uk |
Scientific
Aristotle University of Thessaloniki.
Cardiothoracic Department
AHEPA University Hospital
S. Kyriakidi 1
Thessaloniki
546 36
Greece
Scientific
Inselspital, Universitätsspital Bern
Herz- und Gefässchirurgie
Freiburgstrasse
Bern
CH-3010
Switzerland
Scientific
Universitätsklinikum Ulm
Klinik für Herz-, Thorax- und Gefäßchirurgie
Albert-Einstein-Allee 23
Ulm
89081
Germany
Scientific
Klinikum Braunschweig
Klinik für Herz-, Thorax- und Gefäßchirurgie
Salzdahlumerstrasse 90
Braunschweig
38126
Germany
Scientific
Numune Egitim Arastirma Hastanesi
Kalp Damar Cerrahisi
Talatpasa blvd No:5
Ankara
06100
Türkiye
Scientific
Saud Al Babtain Cardiac Center
Ghirnatah
5443 King Khalid
Dammam
32245
Saudi Arabia
Study information
| Study design | Randomized; Interventional; Design type: Treatment, Surgery |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Participant information sheet | The patient information sheet can be made available on request email: comics-trial@bristol.ac.uk |
| Scientific title | Conventional versus Minimally Invasive extra-corporeal circulation in patients undergoing Cardiac Surgery: a randomised controlled trial |
| Study acronym | COMICS |
| Study hypothesis | The primary hypothesis is that, compared to CECC, using MiECC during cardiac surgery reduces the proportion of patients experiencing post-operative morbidity. The proposed trial will overcome most limitations of previous trials of MiECC. It will: (a) evaluate MiECC system that meet specified criteria which are used in participating centres; (b) be large enough to influence clinical practice, since it will be able to detect a worthwhile benefit in an outcome relevant to patients, surgeons and health services; (c) include a range of features to prevent bias. |
| Ethics approval(s) | South West – Central Bristol Research Ethics Committee, 29/11/2017 |
| Condition | Cardiac surgery |
| Intervention | This study is a multi-centre, two-group parallel randomised controlled trial to investigate the effects of using MiECC in all patients having elective or urgent coronary artery bypass grafting (CABG), aortic valve replacement (AVR) or CABG+AVR using extra-corporeal circulation without circulatory arrest. The research objectives are addressed by randomising participants (1:1 ratio) to have surgery using MiECC system or CECC. Patients undergoing any elective or urgent CABG, AVR, or CABG+AVR, with extra-corporeal circulation and without circulatory arrest are invited to participate. Potential trial participants are identified from operating lists. All potential participants are sent or given an invitation letter and a PIL describing the study. Randomisation take place as close to surgery as possible and is performed by an authorised member of the local research team not involved in post-operative data collection. Participants and members of the local research team responsible for data collection are blind to the allocation. The intervention is applied only for the duration of extra-corporeal circulation without circulatory arrest. Participants are followed up twice, at 30 days and 90 days after surgery: questions elicit information about SAEs experienced since discharge (including readmissions) at 30 days and HRQoL (using the EQ-5D-5L) will be assessed at both times. |
| Intervention type | Other |
| Primary outcome measure | Composite of post-operative serious adverse events (SAEs) are measured using questions to patients during hospital stay and at 30 days post randomisation via a postal or telephone questionnaire. All SAEs that qualify for the primary outcome will be objectively defined and validated. The following events will qualify: 1. Death 2. Myocardial infarction (MI; suspected events will be documented by serum troponin concentrations and electrocardiograph recording (ECG) and adjudicated) 3. Stroke (report of brain imaging (CT or MRI), in association with new onset focal or generalised neurological deficit) 4. Gut infarction (diagnosed by laparotomy or post mortem) 5. AKI Network criteria for stage 3 AKI [16] 6. Reintubation 7. Tracheostomy 8. Mechanical ventilation for >48 hours, including multiple episodes when separated by more than 12 hours 9. Reoperation 10. Percutaneous intervention 11. Sternal wound infection with dehiscence 12. Septicaemia confirmed by microbiology |
| Secondary outcome measures | 1. All-cause mortality is measured using questionnaires 30 days after randomisation 2. Other SAEs are measured using questionnaires 30 days after randomisation 3. Units of RBC transfused up to 30 days after randomisation 4. Other blood products transfused up to 30 days after randomisation 5. Time to discharge from cardiac ICU is measured using patient notes during the index admission 6. Time to discharge from hospital is measured using patient notes following the index admission 7. Delirium in ICU, assessed with the Intensive Care Delirium Screening Checklist (ICDSC) [17] for up to 5 days; this outcome will only be collected in a subset of participating hospitals that have the capability to do so. 8. Health related quality of life is measured using the HRQoL using the EQ-5D-5L [18] up to 90 days after randomisation; responses to this instrument can be mapped on to ‘valuations’ for the economic evaluation 9. Health and social care resources and associated costs up to 90 days after randomisation are measured using the patient in hospital stay and again at 30 and 90 days post randomisation via a postal or telephone questionnaire |
| Overall study start date | 18/01/2017 |
| Overall study end date | 01/12/2020 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Upper age limit | 85 Years |
| Sex | Both |
| Target number of participants | Planned Sample Size: 3500; UK Sample Size: 650 |
| Total final enrolment | 1071 |
| Participant inclusion criteria | 1. Age ≥18 and <85 years 2. Undergoing any elective or urgent CABG, AVR surgery, or CABG+AVR surgery, using extra-corporeal circulation without circulatory arrest |
| Participant exclusion criteria | 1. Requirement for emergency or salvage operation 2. Requirement for major aortic surgery (e.g. aortic root replacement) 3. Contraindication or objection (e.g. Jehovah’s Witnesses) to transfusion of blood products 4. Congenital or acquired platelet, red cell or clotting disorders (patients with iron deficient anaemia will not be excluded) 5. Inability to give informed consent for the study (e.g. learning or language difficulties) |
| Recruitment start date | 05/02/2018 |
| Recruitment end date | 01/12/2020 |
Locations
Countries of recruitment
- England
- Germany
- Greece
- Saudi Arabia
- Switzerland
- Türkiye
- United Kingdom
Study participating centres
Bristol
BS2 8HW
United Kingdom
Crownhill
Plymouth
PL6 8DH
United Kingdom
Shepherd's Bush
London
W12 0HS
United Kingdom
Cottingham
HU16 5JQ
United Kingdom
Cambridge Biomedical Campus
Cambridge
CB2 0AY
United Kingdom
541 24
Greece
Bern
3010
Switzerland
Ulm
89081
Germany
Braunschweig
38114
Germany
Ankara
06230
Türkiye
5443 King Khalid
Dammam
32245
Saudi Arabia
Sponsor information
Hospital/treatment centre
Senate House
Tyndall Avenue
Bristol
BS8 1TH
England
United Kingdom
"ROR" |
https://ror.org/0524sp257 |
|---|
Funders
Funder type
Charity
No information available
Results and Publications
| Intention to publish date | 01/12/2021 |
|---|---|
| Individual participant data (IPD) Intention to share | Yes |
| IPD sharing plan summary | Available on request |
| Publication and dissemination plan | Planned publication in a high-impact peer-reviewed journal. The protocol can be made available on request email: comics-trial@bristol.ac.uk |
| IPD sharing plan | At the end of the study, once analysed, anonymised datasets generated during the study can be available on request, please contact bristol-cteu@bristol.ac.uk. |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Protocol article | 12/08/2020 | 27/02/2023 | Yes | No | |
| Protocol file | version 3.0 | 20/07/2023 | No | No | |
| Plain English results | 21/07/2023 | No | Yes | ||
| Basic results | 29/02/2024 | 29/02/2024 | No | No |
Additional files
Editorial Notes
29/02/2024: Basic results uploaded.
21/07/2023: Plain English results uploaded.
20/07/2023: Protocol file uploaded.
06/07/2023: Contact details updated, total final enrolment added.
27/02/2023: Publication reference added.
13/07/2020: The trial contact details have been made publicly visible.
21/10/2019: Internal review.
09/05/2019: The plain English summary has been updated to include further contacts.
08/05/2019: The following changes were made to the trial record:
1. Professor Kyriakos Anastasiadis was added as a scientific contact.
2. Professor Thierry Carrel was added as a scientific contact.
3. Professor Andreas Liebold was added as a scientific contact.
4. Dr Aschraf El-Essawi was added as a scientific contact.
5. Professor Serdar Gunaydin was added as a scientific contact.
6. Dr Farouk Queida was added as a scientific contact.
7. Royal Papworth Hospital (UK) was added as a trial participating centre.
8. Aristotle University of Thessaloniki. (Greece) was added as a trial participating centre.
9. Inselspital, Universitätsspital Bern (Switzerland) was added as a trial participating centre.
10. Universitätsklinikum Ulm (Germany) was added as a trial participating centre.
11. Klinikum Braunschweig (Germany) was added as a trial participating centre.
12. Ankara Numune Egitim Arastirma Hastanesi (Turkey) was added as a trial participating centre.
13. Saud Al Babtain Cardiac Center (Saudi Arabia) was added as a trial participating centre.
14. The plain English summary has been updated to reflect these changes.
28/03/2019: The condition has been changed from "Specialty: Surgery, Primary sub-specialty: Cardiothoracic Surgery; UKCRC code/ Disease: Cardiovascular/ Other and unspecified disorders of the circulatory system" to "Cardiac surgery" following a request from the NIHR.
